[
  {
    "subtypeText": "NULL", 
    "validationResults": [
      {
        "message": null, 
        "level": null
      }
    ], 
    "drugResistance": [
      {
        "version": {
          "text": "8.4", 
          "publishDate": "2017-06-16"
        }, 
        "drugScores": [
          {
            "text": "Intermediate Resistance", 
            "drugClass": {
              "name": "NRTI"
            }, 
            "score": 50.0, 
            "drug": {
              "displayAbbr": "ABC", 
              "name": "ABC"
            }, 
            "partialScores": [
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "V75I", 
                    "comments": [
                      {
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "M184V", 
                    "comments": [
                      {
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "T215Y", 
                    "comments": [
                      {
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }, 
                  {
                    "text": "T215FY", 
                    "comments": [
                      {
                        "text": "T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "High-Level Resistance", 
            "drugClass": {
              "name": "NRTI"
            }, 
            "score": 60.0, 
            "drug": {
              "displayAbbr": "AZT", 
              "name": "AZT"
            }, 
            "partialScores": [
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "V75I", 
                    "comments": [
                      {
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": -10.0, 
                "mutations": [
                  {
                    "text": "M184V", 
                    "comments": [
                      {
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 40.0, 
                "mutations": [
                  {
                    "text": "T215Y", 
                    "comments": [
                      {
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }, 
                  {
                    "text": "T215FY", 
                    "comments": [
                      {
                        "text": "T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "High-Level Resistance", 
            "drugClass": {
              "name": "NRTI"
            }, 
            "score": 60.0, 
            "drug": {
              "displayAbbr": "D4T", 
              "name": "D4T"
            }, 
            "partialScores": [
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "V75I", 
                    "comments": [
                      {
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": -10.0, 
                "mutations": [
                  {
                    "text": "M184V", 
                    "comments": [
                      {
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 40.0, 
                "mutations": [
                  {
                    "text": "T215Y", 
                    "comments": [
                      {
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }, 
                  {
                    "text": "T215FY", 
                    "comments": [
                      {
                        "text": "T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "Intermediate Resistance", 
            "drugClass": {
              "name": "NRTI"
            }, 
            "score": 50.0, 
            "drug": {
              "displayAbbr": "DDI", 
              "name": "DDI"
            }, 
            "partialScores": [
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "V75I", 
                    "comments": [
                      {
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "M184V", 
                    "comments": [
                      {
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "T215Y", 
                    "comments": [
                      {
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }, 
                  {
                    "text": "T215FY", 
                    "comments": [
                      {
                        "text": "T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "High-Level Resistance", 
            "drugClass": {
              "name": "NRTI"
            }, 
            "score": 70.0, 
            "drug": {
              "displayAbbr": "FTC", 
              "name": "FTC"
            }, 
            "partialScores": [
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "V75I", 
                    "comments": [
                      {
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 60.0, 
                "mutations": [
                  {
                    "text": "M184V", 
                    "comments": [
                      {
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }, 
                  {
                    "text": "T215FY", 
                    "comments": [
                      {
                        "text": "T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "High-Level Resistance", 
            "drugClass": {
              "name": "NRTI"
            }, 
            "score": 70.0, 
            "drug": {
              "displayAbbr": "3TC", 
              "name": "LMV"
            }, 
            "partialScores": [
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "V75I", 
                    "comments": [
                      {
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 60.0, 
                "mutations": [
                  {
                    "text": "M184V", 
                    "comments": [
                      {
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }, 
                  {
                    "text": "T215FY", 
                    "comments": [
                      {
                        "text": "T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "Low-Level Resistance", 
            "drugClass": {
              "name": "NRTI"
            }, 
            "score": 20.0, 
            "drug": {
              "displayAbbr": "TDF", 
              "name": "TDF"
            }, 
            "partialScores": [
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "V75I", 
                    "comments": [
                      {
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": -10.0, 
                "mutations": [
                  {
                    "text": "M184V", 
                    "comments": [
                      {
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "T215Y", 
                    "comments": [
                      {
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "M41L", 
                    "comments": [
                      {
                        "text": "M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }, 
                  {
                    "text": "T215FY", 
                    "comments": [
                      {
                        "text": "T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.", 
                        "type": "NRTI"
                      }
                    ], 
                    "primaryType": "NRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "High-Level Resistance", 
            "drugClass": {
              "name": "NNRTI"
            }, 
            "score": 60.0, 
            "drug": {
              "displayAbbr": "EFV", 
              "name": "EFV"
            }, 
            "partialScores": [
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 30.0, 
                "mutations": [
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "H221Y", 
                    "comments": [
                      {
                        "text": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }, 
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "Intermediate Resistance", 
            "drugClass": {
              "name": "NNRTI"
            }, 
            "score": 55.0, 
            "drug": {
              "displayAbbr": "ETR", 
              "name": "ETR"
            }, 
            "partialScores": [
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 30.0, 
                "mutations": [
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 10.0, 
                "mutations": [
                  {
                    "text": "H221Y", 
                    "comments": [
                      {
                        "text": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }, 
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "High-Level Resistance", 
            "drugClass": {
              "name": "NNRTI"
            }, 
            "score": 110.0, 
            "drug": {
              "displayAbbr": "NVP", 
              "name": "NVP"
            }, 
            "partialScores": [
              {
                "score": 30.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 60.0, 
                "mutations": [
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "H221Y", 
                    "comments": [
                      {
                        "text": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }, 
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }
            ]
          }, 
          {
            "text": "High-Level Resistance", 
            "drugClass": {
              "name": "NNRTI"
            }, 
            "score": 80.0, 
            "drug": {
              "displayAbbr": "RPV", 
              "name": "RPV"
            }, 
            "partialScores": [
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 45.0, 
                "mutations": [
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 15.0, 
                "mutations": [
                  {
                    "text": "H221Y", 
                    "comments": [
                      {
                        "text": "H221Y is a non-polymorphic accessory mutation selected primarily by NVP and RPV. It frequently occurs in combination with Y181C.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }, 
              {
                "score": 5.0, 
                "mutations": [
                  {
                    "text": "A98G", 
                    "comments": [
                      {
                        "text": "A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }, 
                  {
                    "text": "Y181C", 
                    "comments": [
                      {
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving each of the NNRTIs. It causes high-level reduction in NVP susceptibility, intermediate-level reduction in RPV and ETR susceptibility, and low-level reduction in EFV susceptibility. Y181C has a high weight in the Tibotec ETR genotypic susceptibility score.", 
                        "type": "NNRTI"
                      }
                    ], 
                    "primaryType": "NNRTI"
                  }
                ]
              }
            ]
          }
        ], 
        "gene": {
          "name": "RT"
        }
      }
    ], 
    "alignedGeneSequences": [
      {
        "prettyPairwise": {
          "mutationLine": [
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " R ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " T ", 
            " - ", 
            " - ", 
            " - ", 
            " E ", 
            " - ", 
            " L ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " T ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " I ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " I ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " G ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " R ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " E ", 
            " S ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " L ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " T ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " A ", 
            " - ", 
            " - ", 
            " - ", 
            " E ", 
            " - ", 
            " - ", 
            " - ", 
            " C ", 
            " - ", 
            " - ", 
            " V ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " A ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " E ", 
            " - ", 
            " - ", 
            " - ", 
            " K ", 
            " - ", 
            " - ", 
            " LF", 
            " Y ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " Y ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " Q ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " P ", 
            " - ", 
            " - ", 
            " R ", 
            " - ", 
            " R ", 
            " H ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " A ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " D ", 
            " I ", 
            " V ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " N ", 
            " D ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " K ", 
            " RM", 
            " - ", 
            " T ", 
            " T ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " V ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " L ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " TI", 
            " - ", 
            " - ", 
            " - ", 
            " R ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " I ", 
            " - ", 
            " - ", 
            " - ", 
            " D ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " - ", 
            " D ", 
            " - ", 
            " - ", 
            " A ", 
            " E ", 
            " V "
          ], 
          "refAALine": [], 
          "alignedNAsLine": [], 
          "positionLine": []
        }, 
        "firstAA": null, 
        "lastAA": null, 
        "mutations": []
      }
    ], 
    "inputSequence": {
      "header": "", 
      "SHA512": ""
    }
  }
]